Evaluation eines dominant-negativen rekombinanten Herpes-simplex-Virus (HSV) Typ 1 als Impfstoff gegen Herpes genitalis bei Mäusen und Meerschweinchen

Titelvariante(n): Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs
Autor(en): Brans, Richard 
Affiliationen: Fachgebiet Dermatologie, Umweltmedizin und Gesundheitstheorie, Universität Osnabrück, Sedanstr. 115, 49090, Osnabrück. rbrans@uni-osnabrueck.de
Erscheinungsdatum: 2010
Journal: Der Hautarzt : Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Volumen: 61
Ausgabe: 12
Startseite: 1073
Seitenende: 1078
Zusammenfassung: 
Genital herpes caused by herpes simplex virus (HSV) is one of the most common sexually transmitted diseases worldwide. Currently, no safe and effective vaccine against HSV is available. CJ9-gD is a completely replication-defective HSV-1 recombinant which inhibits replication of wild-type HSV-1/-2 in co-infected cells (dominant-negative effect). Moreover, it expresses high levels of HSV-1 major antigen glycoprotein D (gD). Immunization with CJ9-gD induces strong and long-lasting humoral and Th1-like cellular immune responses against both HSV-1 and HSV-2 in mice protecting immunized animals significantly against genital challenge with HSV-1 or HSV-2. Guinea pigs immunized with CJ9-gD were significantly protected against primary and recurrent HSV-2 genital disease and latent infection.
DOI: 10.1007/s00105-010-2075-8

Show full item record

Page view(s)

1
Last Week
0
Last month
1
checked on Apr 23, 2024

Google ScholarTM

Check

Altmetric